This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 G30.0 — Alzheimer disease with early onset Special Copayment Reduction: V800

Alzheimer disease with early onset알츠하이머병, 조기 발병

Synonyms and related terms: Early-onset Alzheimer disease (EOAD), presenile Alzheimer disease

ICD-10 dual coding guidance
G30.0 is a dagger (†) code describing the underlying neurological disease (Alzheimer disease with early onset), and the accompanying dementia syndrome is additionally coded with the asterisk (*) code F00.0* (dementia in Alzheimer disease with early onset). On claims, enter them in the order G30.0† F00.0*, with G30.0† as the principal diagnosis. This follows the principle of the WHO ICD-10 dual coding system, which reflects both the neurological etiology and the psychobehavioral syndrome at the same time.
Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The history of Alzheimer disease (AD) began in 1906, when the German neuropsychiatrist Alois Alzheimer described senile plaques and neurofibrillary tangles (NFT) in the autopsied brain of Auguste Deter, a woman who developed progressive memory impairment, aphasia, apraxia, and paranoid symptoms at age 51 and died at age 56. Alzheimer presented this case at the Meeting of South-West German Psychiatrists in November 1906 and published it in a paper in 1907.

Subsequently, Emil Kraepelin named the disease 'Alzheimer's disease' in his 1910 textbook, and a dichotomy distinguishing onset before age 65 as presenile dementia and onset at 65 or later as senile dementia was maintained for decades. In the 1970s, studies by Robert Terry, Gary Bhyas, and others showed that senile dementia and presenile Alzheimer disease share the same pathology, and the two were unified into a single disease concept regardless of age. In 1984, Glenner and Wong determined the amyloid beta (Aβ) protein sequence, and in 1986, Wischniewski et al. showed that tau protein is the main component of NFT.

In the 1990s, APP (1991), PSEN1 (1995), and PSEN2 (1995) were successively discovered as causative genes of familial early-onset Alzheimer disease (EOAD), establishing genetic evidence for the amyloid cascade hypothesis. The 2018 NIA-AA research framework introduced a pathobiological definition (A/T/N biomarker classification), defining the Alzheimer continuum from the stage before clinical symptoms, and laid the foundation for developing anti-amyloid monoclonal antibody (lecanemab, donanemab) treatments.

2. Causes

Early-onset Alzheimer disease (early-onset AD, EOAD) is Alzheimer disease with onset before age 65, especially at ages 40-64, and accounts for about 5-10% of all AD. The causative genes of familial EOAD identified are APP (amyloid precursor protein), PSEN1 (presenilin 1), and PSEN2 (presenilin 2), of which PSEN1 variants are the most common. Pathogenic variants in these genes cause abnormal gamma-secretase activity, altering the cleavage site of amyloid precursor protein (APP) and resulting in relative overproduction of the highly aggregation-prone Aβ42 peptide, which accelerates amyloid deposition in the brain.

Sporadic EOAD also accounts for a considerable proportion, and although the APOE ε4 allele is associated with increased risk, the effect of APOE ε4 in early-onset AD is somewhat weaker than in late-onset AD (LOAD). Recent genome-wide association studies (GWAS) have identified multiple risk gene loci, including TREM2, BIN1, CLU, and PICALM, which are involved in immune, synaptic, and lipid metabolism pathways. Among non-genetic factors, Down syndrome (trisomy 21, APP gene duplication), head trauma, and cardiovascular risk factors are known to increase EOAD risk.

3. Genetics

The causative genes of familial EOAD are summarized as three major genes. PSEN1 (14q24.2) accounts for about 50-70% of familial EOAD, and more than 300 pathogenic variants have been reported. PSEN1 variants show complete penetrance, and the age of onset varies by variant type but is usually in the 30s to 60s. In particular, the Antioquia, Colombia cohort carrying the PSEN1 p.Glu280Ala variant has been studied as the world's largest familial EOAD population.

APP (21q21.3) variants account for about 10-15% of familial EOAD, with V717I (London mutation), V717F, and K670N/M671L (Swedish mutation) being representative. In particular, the APP K670N/M671L double variant increases beta-secretase (BACE1) cleavage efficiency, greatly increasing Aβ production. Patients with trisomy of chromosome 21 (Down syndrome) show Alzheimer pathology in their 40s to 50s almost without exception because of APP gene overexpression.

PSEN2 (1q42.13) variants are rare, accounting for less than about 5% of familial EOAD, and N141I (Volga German mutation) and others have been reported. PSEN2 variants may show incomplete penetrance and a late age of onset (50s to 80s), so they can overlap clinically with LOAD. The APOE ε4 allele increases risk in both familial and sporadic EOAD, but the additional effect of APOE ε4 in carriers of PSEN1/APP variants is limited.

4. General epidemiology

Alzheimer disease is the most common cause of dementia worldwide, accounting for about 60-70% of all dementia. According to the 2023 World Alzheimer Report (Alzheimer Disease International), the number of people living with dementia worldwide is about 55 million, with 10 million new cases occurring each year. In Korea, according to the 2022 Central Dementia Center report, the number of people with dementia is about 920,000, and it is estimated that 1 in 10 people aged 65 and older has dementia.

Early-onset Alzheimer disease (EOAD, onset before age 65) accounts for about 5-10% of all AD, with a reported prevalence of about 24-45 per 100,000 population. The younger the age of onset, the higher the proportion of familial causes, and PSEN1, APP, and PSEN2 variants are identified in a considerable number of cases with onset before age 45. EOAD differs clinically in that atypical phenotypes with prominent non-memory cognitive symptoms (aphasia, apraxia, visuospatial deficits) are more frequent than in LOAD. Prevalence by age rises steeply, from about 2% at age 65 to 30-40% at age 85.

5. Pathophysiology

The core pathogenesis of Alzheimer disease is the amyloid cascade hypothesis, which holds that abnormal accumulation of Aβ peptide in the brain is the starting point of a chain reaction leading to neurotoxic tau pathology, synapse loss, and neuronal death. APP is cleaved sequentially by α-, β-, and γ-secretases, and Aβ peptide is produced in the amyloidogenic pathway by β-secretase (BACE1) and γ-secretase (including PSEN1/2). Aβ42 is more hydrophobic and aggregates faster than Aβ40, and leads the nucleation of early amyloid plaques.

Soluble Aβ oligomers show higher synaptic toxicity than mature plaques, causing synapse loss and suppression of long-term potentiation (LTP) through disruption of NMDA receptor signaling, mitochondrial dysfunction, and induction of oxidative stress. Following Aβ deposition, hyperphosphorylated tau detaches from microtubules to form paired helical filaments (PHF) and constitutes intracellular NFT, and through prion-like propagation of tau, the lesions progress stepwise throughout the cerebral cortex according to Braak stages (I-VI).

In EOAD, amyloid pathology progresses faster and more extensively than in LOAD, and tau pathology sometimes shows an atypical distribution (visual cortex, language cortex, etc.), which is associated with non-memory clinical phenotypes. Neuroinflammatory mechanisms involve impaired Aβ phagocytosis by microglia through the TREM2 receptor, complement system activation, and elevated inflammatory cytokines such as IL-1β and TNF-α. Loss of basal forebrain cholinergic neurons progresses centered on the nucleus basalis of Meynert (nbM), reducing cerebral cortical cholinergic signaling, which is the pharmacological rationale for cholinesterase inhibitor treatment.

6. Symptoms

Compared with late-onset (LOAD), early-onset Alzheimer disease (EOAD) shows more prominent early impairment in non-memory cognitive domains. In about 30-40% of EOAD cases, atypical phenotypes such as visuospatial deficits (posterior cortical atrophy), language deficits (logopenic variant PPA), and executive dysfunction (frontal variant) appear as initial symptoms instead of typical memory impairment. Visuospatial deficits due to posterior parietal cortical atrophy manifest as reading difficulty, drawing copy errors, loss of spatial orientation, and impaired object recognition.

In the typical phenotype, episodic memory impairment is the most prominent early on, especially marked impairment of encoding new information and delayed recall. This is directly related to neuronal loss in the hippocampus and entorhinal cortex. Impaired temporal orientation (recent date, day of the week), repeated questions, and forgetting recent conversations are the earliest symptoms recognized by informants. Language decline appears as naming errors, word-finding difficulty, and reduced fluency, and as the disease progresses, auditory comprehension, reading, and writing are also affected.

As behavioral and psychological symptoms (BPSD), depression, anxiety, apathy, and sleep disturbance may appear early, and agitation, wandering, delusions (especially delusions of theft), and hallucinations are added from the middle stage onward. In the decline of activities of daily living (ADL), instrumental ADL (IADL: managing finances, taking medication, using public transportation) is affected first, followed by impairment of basic ADL (eating, hygiene, dressing).

7. Signs

On neurological examination, in early Alzheimer disease there is usually no obvious focal neurological deficit. However, in EOAD with the posterior cortical atrophy (PCA) phenotype, neurological signs related to visual processing may be observed. Components of Balint syndrome—ocular motor apraxia, simultanagnosia, and optic ataxia—may appear, reflecting extensive damage to the parieto-occipital cortex.

On neuropsychological testing, in addition to decreased MMSE/MoCA scores, decreased immediate and delayed recall on the Rey Complex Figure Test (RCFT), naming errors on the Boston Naming Test, and decreased semantic fluency on verbal fluency tests are typical findings of EOAD. Motor signs are often preserved until late, but in the terminal stage muscle rigidity, gait disturbance, dysphagia, and incontinence appear. Seizures occur more frequently in EOAD than in LOAD, and myoclonic seizures are relatively common, especially in PSEN1 variant carriers.

On neurological examination, the appearance of primitive reflexes (grasp reflex, grimace reflex) suggests frontal lobe dysfunction, and in the terminal stage limb rigidity, flexion posture (decorticate posturing), and dysphagia progress, raising the risk of aspiration pneumonia.

8. Screening

The most widely used tools for cognitive screening in Alzheimer disease are the Mini-Mental State Examination (MMSE, Folstein 1975) and the Montreal Cognitive Assessment (MoCA, Nasreddine 2005). The MMSE has a maximum of 30 points and is simple to administer, but its sensitivity is low at the mild cognitive impairment (MCI) stage and it is affected by educational level. The MoCA includes domains that the MMSE does not assess sufficiently, such as executive function, visuospatial ability, and attention, and is more sensitive for MCI screening (sensitivity about 90%, specificity about 87%). In Korea, the MMSE-KC (Korean version of the Mini-Mental State Examination) and MoCA-K are used with standardized norms.

The Korean Dementia Screening Questionnaire (KDSQ-C) is a 15-item caregiver-report instrument that can be used in primary care. The AD8 (Ascertaining Dementia 8) is an 8-item screening tool answered by the caregiver, and further evaluation is recommended if 2 or more items are abnormal. When EOAD is suspected, multidomain cognitive function is quantitatively assessed with standard neuropsychological test batteries (Seoul Neuropsychological Screening Battery, CERAD-K, SNSB-II), and detailed assessment of verbal memory, visuospatial function, and executive function is particularly needed.

Brain MRI (3T, volumetric) is recommended for quantifying hippocampal atrophy, assessing entorhinal cortex atrophy, and excluding vascular lesions, and automated segmentation for hippocampal volumetry (FreeSurfer, etc.) is being introduced in research and clinical settings. FDG-PET shows a parietotemporal hypometabolism pattern, and amyloid PET (18F-florbetapir, 18F-florbetaben, 18F-flutemetamol) visualizes brain amyloid deposition, enabling confirmation of etiology during life.

9. Diagnosis

The clinical diagnosis of Alzheimer disease is based on the 2011 NIA-AA diagnostic criteria (McKhann et al.) and the 2018 NIA-AA research framework (Jack et al.). The 2011 criteria classify the clinical diagnosis as possible, probable, or definite AD, and a diagnosis of probable AD must satisfy (1) insidious onset of cognitive decline, (2) clear cognitive worsening confirmed by history or testing, (3) impairment in one or more cognitive domains, including memory impairment, and (4) exclusion of other causes.

The 2018 NIA-AA research framework introduced the A (amyloid)/T (tau)/N (neurodegeneration) biomarker system to define the Alzheimer continuum pathobiologically. Stages are distinguished by combinations of A+ (decreased CSF Aβ42 or positive amyloid PET), T+ (elevated CSF p-tau or positive tau PET), and N+ (elevated CSF total tau, FDG-PET hypometabolism, MRI atrophy). The Alzheimer continuum is established by A+ alone, and biological Alzheimer disease is defined regardless of the presence of clinical symptoms.

Among CSF biomarkers, the combination of decreased Aβ42 (or decreased Aβ42/Aβ40 ratio), elevated p-tau181/217/231, and elevated total tau shows high accuracy for diagnosing Alzheimer disease. Plasma biomarkers (plasma p-tau217, p-tau181, Aβ42/Aβ40 ratio, GFAP, NfL) have recently entered the stage of clinical introduction, making it possible to confirm AD pathology without invasive CSF testing. Histopathological confirmation is made by evaluating amyloid plaque density according to CERAD criteria and determining Braak tau stage in autopsy or biopsy brain tissue.

10. Treatment

Treatment of Alzheimer disease is divided into symptomatic treatment and disease-modifying therapy (DMT). The core of symptomatic treatment is cholinesterase inhibitors (AChEI); donepezil, rivastigmine, and galantamine have evidence for improving cognitive function and ability in daily activities in mild to moderate AD. Memantine (an NMDA receptor antagonist) is recommended alone or in combination with an AChEI in moderate to severe AD.

Anti-amyloid monoclonal antibodies are the first disease-modifying treatments; lecanemab (Leqembi) was approved by the US FDA in 2023, and donanemab also received FDA approval in 2024. Lecanemab is an IgG1 antibody that selectively binds soluble Aβ protofibrils; in the CLARITY AD phase 3 trial it delayed clinical decline by about 27% over 18 months, and it is administered by intravenous infusion twice a year. Donanemab binds pyroglutamate-Aβ in amyloid plaques and delayed clinical decline by about 22-35% in the TRAILBLAZER-ALZ2 trial.

The main adverse effect of anti-amyloid therapy is amyloid-related imaging abnormalities (ARIA), which appear as ARIA-E (cerebral edema) and ARIA-H (microhemorrhage). Confirmation of A+ by amyloid PET or CSF testing before treatment is essential, and APOE ε4 homozygotes have a high risk of ARIA, so caution is needed in selecting indications. In Korea, the application of National Health Insurance coverage criteria and treatment guidelines is in progress.

As nonpharmacological treatment, cognitive stimulation therapy (CST), cognitive rehabilitation, occupational therapy, and exercise therapy play a supportive role in maintaining cognitive function and quality of life. For BPSD management, nonpharmacological approaches (environmental modification, behavioral therapy) are prioritized, and low-dose antipsychotics are used short term when necessary.

11. Prognosis

Alzheimer disease is a progressive, irreversible neurodegenerative disease with a generally poor prognosis. The average survival after diagnosis is about 8-12 years, but individual variation is large. EOAD tends to have a lower age of onset and faster disease progression than LOAD, and some studies have reported that the median survival of EOAD patients is shorter than that of LOAD. In particular, PSEN1 variant carriers often show rapid progression.

The clinical course may remain stable for several years at the mild cognitive impairment (MCI) stage, but once it progresses to mild AD, progression at a rate of about 1 point per year in CDR score is typical. Clinical Dementia Rating (CDR) sum of boxes, ADAS-Cog, and ADCS-ADL are used as indicators of functional decline. The causes of death are mainly complications such as aspiration pneumonia, urinary tract infection, and pressure ulcer-related sepsis, and in most cases death results from general debilitation and infection rather than direct neurological damage.

Age at diagnosis, initial rate of cognitive decline, rate of brain imaging atrophy, plasma NfL level, and APOE genotype are used as prognostic predictors, and the possibility of delaying disease progression at an early stage after the introduction of anti-amyloid therapy is expected to contribute to improved prognosis.

12. Prevention

There is not yet an established primary prevention method for Alzheimer disease, but management of modifiable risk factors is the core of prevention strategy. The 2020 Lancet Commission on dementia prevention report estimated that 12 modifiable risk factors (low educational level, hearing loss, hypertension, obesity, smoking, depression, physical inactivity, diabetes, excessive alcohol consumption, air pollution, head trauma, social isolation) contribute to about 40% of dementia worldwide. Evidence is accumulating that active management of these risk factors can significantly lower the risk of developing AD.

The FINGER (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) clinical trial was the first to show that multidomain intervention (diet, exercise, cognitive training, cardiovascular risk monitoring) significantly mitigates cognitive decline, and the World-Wide FINGERS network based on it is spreading globally. Preventive anti-amyloid intervention trials in carriers of familial EOAD (PSEN1/APP/PSEN2 variants) (API APOE4 Trial, DIAN-TU) are under way, exploring the possibility of preemptive treatment in the presymptomatic stage.

APOE ε4 genotyping is currently not recommended for general screening purposes, but may be provided together with genetic counseling in the context of research participation, clinical decision-making, and counseling of high-risk family members. In Korea, under the national dementia responsibility policy, cognitive screening for those aged 60 and older through dementia relief centers, early diagnosis, and a community management system have been established.

13. References